| Literature DB >> 28950145 |
Tomonari Kinoshita1, Chie Kudo-Saito2, Reiko Muramatsu3, Tomonobu Fujita3, Miyuki Saito3, Haruna Nagumo3, Toshiharu Sakurai3, Shinobu Noji3, Emi Takahata3, Tomonori Yaguchi3, Nobuo Tsukamoto3, Yuichiro Hayashi4, Kaoru Kaseda5, Ikuo Kamiyama5, Takashi Ohtsuka5, Kenji Tomizawa6, Masaki Shimoji6, Tetsuya Mitsudomi6, Hisao Asamura5, Yutaka Kawakami7.
Abstract
We have previously demonstrated that the prognostic significance of tumour-infiltrating CD8+ T cells significantly differs according to histological type and patient smoking habits in non-small cell lung cancer (NSCLC). This work suggested that infiltrating CD8+ T cells may not be activated sufficiently in the immunosuppressive microenvironment in non-smokers with adenocarcinoma. To understand the immunogenic microenvironment in NSCLC, we characterised immune cells comprehensively by performing an immunohistochemical evaluation using an alternative counting method and multicolour staining method (n = 234), and assessed immune-related gene expression by using genetic analytical approaches (n = 58). We found that high infiltration of activated CD8+ T cells expressing interferon gamma (IFN-γ) and granzyme was correlated with postoperative survival in patients with non-adenocarcinoma. On the contrary, CD8+ T-cell accumulation was identified as a worse prognostic factor in patients with adenocarcinoma, particularly in non-smokers. Infiltrating CD8+ T cells were significantly less activated in this microenvironment with high expression of various immunoregulation genes. Potentially immunoregulatory CD8+ FOXP3+ T cells and immunodysfunctional CD8+ GATA3+ T cells were increased in adenocarcinoma of non-smokers. CD4+ FOXP3+ regulatory T cells expressing chemokine receptor-4 (CCR4)- and chemokine ligand (CCL17)-expressing CD163+ M2-like macrophages also accumulated correlatively and significantly in adenocarcinoma of non-smokers. These characteristic immune cells may promote tumour progression possibly by creating an immunosuppressive microenvironment in non-smoking patients with lung adenocarcinoma. Our findings may be helpful for refining the current strategy of personalised immunotherapy including immune-checkpoint blockade therapy for NSCLC.Entities:
Keywords: Adenocarcinoma; Immunosuppression; Non-small cell lung cancer; Smoking history; Tumour microenvironment
Mesh:
Substances:
Year: 2017 PMID: 28950145 DOI: 10.1016/j.ejca.2017.08.026
Source DB: PubMed Journal: Eur J Cancer ISSN: 0959-8049 Impact factor: 9.162